Sign In
Buy NEO
$10.14
+0.0200 (+0.198%)
At Close: Jun 03, 2026
Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) Target Price at $11.86
02:06am, Monday, 23'rd Mar 2026
Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) have been given a consensus recommendation of "Hold" by the fourteen analysts that are currently covering the firm, Marketbeat reports. One
Neo Performance Materials Inc. (NEO:CA) Q4 2025 Earnings Call Transcript
05:22pm, Thursday, 19'th Mar 2026
Neo Performance Materials Inc. (NEO:CA) Q4 2025 Earnings Call Transcript
SBC Medical Announces Opening of Brand Flagship "NEO Skin Clinic Ginza."
08:00am, Monday, 16'th Mar 2026
IRVINE, Calif.--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise
NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
07:05am, Monday, 16'th Mar 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program.
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company deve
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
07:05am, Wednesday, 25'th Feb 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.
Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology
06:00am, Monday, 23'rd Feb 2026
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology.
NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of “Hold” from Brokerages
04:06am, Monday, 23'rd Feb 2026
Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) have been assigned an average rating of "Hold" from the fourteen research firms that are currently covering the stock, MarketBeat.com report
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO)
10:36am, Friday, 20'th Feb 2026
NeoGenomics (NEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin
NeoGenomics to Participate in Upcoming Investor Conferences
07:05am, Wednesday, 18'th Feb 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare Conference in Miami.
NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript
12:55pm, Tuesday, 17'th Feb 2026
NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
09:16am, Tuesday, 17'th Feb 2026
NeoGenomics (NEO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.04 per share a year ago.
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
07:05am, Tuesday, 17'th Feb 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full-year results for the period ended December 31, 2025.
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro
10:01am, Monday, 16'th Feb 2026
NEO launches PanTracer Pro, a pan-solid tumor assay built to streamline genomic testing and speed treatment decisions in advanced cancers.
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
07:05am, Thursday, 12'th Feb 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launches PanTracer Pro, designed to help clinicians navigate complex molecular testing and support informed solid tumor decisions.
